Mtb, the causative agent of the disease tuberculosis, remains the leading worldwide bacterial cause of death. Mtb survives in mononuclear cells, where it successfully combats macrophage microbicidal mechanisms by evading delivery to the lysosome, thereby limiting bacterial degradation 1 . Autophagy can contribute to the degradation of intracellular bacteria (xenophagy) through the formation of autophagosomes that sequester cytoplasmic bacilli and deliver them to lysosomes for degradation. Autophagy is also important for innate and adaptive immune responses, as it promotes antigen presentation and modulates inflammatory responses. Its importance in host immunity is underscored by the observation that many intracellular pathogens have strategies to evade autophagy 2 . In the case of Mtb, when autophagy is stimulated by pharmacological means or interferon-γ (IFN-γ) treatment, targeting of Mtb to autophagosomes and bacterial killing is enhanced [3] [4] [5] . However, in the absence of such stimuli, the majority of Mtb do not associate with LC3, a marker of autophagy. Moreover, in resting macrophages and in vivo in mice, autophagy only makes a modest contribution to the clearance of Mtb 3,6-8 . These observations raise the possibility that Mtb blocks autophagy.
Mtb, the causative agent of the disease tuberculosis, remains the leading worldwide bacterial cause of death. Mtb survives in mononuclear cells, where it successfully combats macrophage microbicidal mechanisms by evading delivery to the lysosome, thereby limiting bacterial degradation 1 . Autophagy can contribute to the degradation of intracellular bacteria (xenophagy) through the formation of autophagosomes that sequester cytoplasmic bacilli and deliver them to lysosomes for degradation. Autophagy is also important for innate and adaptive immune responses, as it promotes antigen presentation and modulates inflammatory responses. Its importance in host immunity is underscored by the observation that many intracellular pathogens have strategies to evade autophagy 2 . In the case of Mtb, when autophagy is stimulated by pharmacological means or interferon-γ (IFN-γ) treatment, targeting of Mtb to autophagosomes and bacterial killing is enhanced [3] [4] [5] . However, in the absence of such stimuli, the majority of Mtb do not associate with LC3, a marker of autophagy. Moreover, in resting macrophages and in vivo in mice, autophagy only makes a modest contribution to the clearance of Mtb 3, [6] [7] [8] . These observations raise the possibility that Mtb blocks autophagy.
During Mtb infection, xenophagy is initiated when mycobacterial DNA is detected by the cytosolic DNA sensor cGAS ('cyclic GMP-AMP synthase') 6, [9] [10] [11] . Once this process is initiated, over 30 proteins, including members of the autophagy-related ATG family, orchestrate sequential membrane remodeling and trafficking events to complete nucleation of the autophagosome membrane (Beclin-1, VPS34 and ATG14L), elongation and maturation of autophagosomes (ATG5, ATG12, ATG16L1, ATG4B, ATG3, ATG7 and LC3), and docking and fusion of lysosomes (Syntaxin17 and UVRAG) 12, 13 . Transcriptional reinforcement is needed to sustain autophagy by replenishing components that are degraded along with captured cargo, such as adaptors that bind cargo (for example, p62) and LC3, which in its phosphatidylethanolamine-conjugated form (LC3-II) is associated with the autophagosomal membrane. The transcription factors FOXO3 (ref. 14) and TFEB 15 , which are activated by the kinase AMPK ('adenosine 5′ monophosphate-activated protein kinase'), accomplish this by promoting the expression of genes encoding products involved in the biogenesis and function of autophagosomes and lysosomes 16, 17 .
Mtb also alters macrophage cellular metabolism to promote the accumulation of lipid bodies, which serve as a source of nutrients in the form of cholesterol esters and fatty acids [18] [19] [20] . These 'foamy' macrophages provide a secure niche for the bacterium by enabling survival, replication and, ultimately, persistence in the human host. The formation of mycobacterial lipid bodies has been shown to be dependent on Toll-like receptor signaling pathways, and isolated components of the mycobacterial cell wall such as lipoarabinomannan can mimic the pathogen and induce lipid-body formation 21 . However, the mechanisms that regulate lipid-body formation in Mtb-infected macrophages remain poorly understood. 
A r t i c l e s
MicroRNAs (miRNAs) have emerged as important posttranscriptional 'fine-tuners' of gene expression in response to pathophysiological stimuli. These small noncoding RNAs bind to the 3′ untranslated region (3′ UTR) of target mRNAs and reduce protein expression by blocking mRNA translation and/or by promoting mRNA degradation. A given miRNA can simultaneously regulate multiple target genes, often encoding products with related functions, which results in potent cumulative effects on gene networks. Notable examples of this mechanism are miR-33a and miR-33b, intronic miRNAs that are embedded in the human genes SREBF2 and SREBF1, respectively, which encode sterol-response-element-binding proteins (mice lack miR-33b) [22] [23] [24] [25] . miR-33a and miR-33b repress genes encoding products involved in cellular cholesterol export and fatty acid oxidation, including ABCA1, CROT, CPT1, HADHB and PRKAA1, and thereby boost cellular lipid levels and lower plasma levels of high-density lipoproteins [22] [23] [24] [25] . Furthermore, although generally one strand of a miRNA duplex 'preferentially' associates with the RNA-induced silencing complex (RISC) and the 'passenger' (miRNA*) strand is degraded, both miR-33 and its passenger strand miR-33* accumulate and target an overlapping subset of genes encoding products involved in lipid metabolism, which suggests that the two strands processed from the miR-33 precursor duplex co-regulate biological pathways 26 .
We found that autophagy was a key pathway targeted by miR-33 and miR-33*. Given that autophagy promotes lipid catabolism (lipophagy) by delivering lipid-droplet-stored triglycerides and cholesterol esters to lysosomes 13, 27 , suppression of autophagy by miR-33 and miR-33* would contribute to the coordinated actions of these miRNAs to promote cellular lipid accumulation. Moreover, we found that Mtb took advantage of this host regulatory circuit by inducing the expression of miR-33 and miR-33* during macrophage infection to simultaneously impair xenophagy and promote fatty-acid stores in lipid bodies to ensure its own intracellular survival.
RESULTS
Induction of the expression of miR-33 and miR-33* by Mtb Because miR-33 boosts cellular sterol levels and is regulated by the transcription factor NF-κB 28 , we surmised that it might drive a metabolic response to Mtb infection. Infection of mouse peritoneal macrophages with the H37Rv strain of Mtb increased expression of miR-33 and its host gene Srebf2 (Fig. 1a) . Notably, Mtb H37Rv induced a parallel increase in miR-33* expression in peritoneal macrophages (Fig. 1a) , and we observed similar results in human THP-1 macrophages (Supplementary Fig. 1 ). Treatment of mouse bone-marrow-derived macrophages (BMDMs) with γ-irradiated Mtb (γ-Mtb) or with purified components of the mycobacterial cell wall (lipoarabinomannan or trehalose dimycolate) increased expression of Srebf2 and the miR-33 precursor transcript from which mature miR-33 and miR-33* arise (Fig. 1b) . Although copy numbers of miR-33* were low compared with those of miR-33 in mouse embryonic fibroblasts (MEFs), miR-33* was relatively abundant in mouse peritoneal macrophages (Fig. 1c) , which suggested that it might be important in this cell type. We immunoprecipitated the RISC subunit Ago2 from peritoneal macrophages and found it had more association with miR-33 and miR-33* in macrophages treated with γ-Mtb than in untreated macrophages (Fig. 1d) ; this demonstrated that both strands of the miR-33 duplex were loaded onto the RISC following Mtb infection.
To investigate whether miR-33 and miR-33* were regulated by Mtb in vivo, we isolated alveolar macrophages from the lungs of mice infected with Mtb expressing green fluorescent protein (GFP). We observed fivefold higher expression of miR-33 and miR-33* in infected (GFP + ) macrophages than in uninfected (GFP − ) macrophages from the same mice (Fig. 1e) . To assess whether NF-κB was required for the induction of miR-33 and miR-33*, we treated BMDMs with the NF-κB inhibitor BAY11-7082 and quantified miRNA expression in response to γ-Mtb infection. BAY11-7082 prevented induction of the expression of Srebf2, miR-33 and miR-33* by γ-Mtb (Fig. 1f) . 
A r t i c l e s
Together these data indicated that miR-33 and miR-33* expression was upregulated in macrophages by Mtb and its cell-wall constituents via an NF-κB-dependent mechanism.
Regulation of lipid-body catabolism by miR-33 and miR-33* Next we investigated whether the expression of miR-33 and miR-33* in Mtb-infected macrophages contributed to the formation of fatty-acid-rich lipid bodies. Using extracellular flux analysis, we quantified the cellular oxygen consumption rate (OCR) as a measure of fatty-acid β-oxidation in unstimulated or γ-Mtb-treated macrophages. Notably, γ-Mtb reduced the OCR in wild-type BMDMs, whereas the OCR was largely restored in Mir33 −/− BMDMs, which lack expression of both miR-33 and miR-33* (Fig. 2a,b) . We quantified neutral lipids in Mtb-infected macrophages treated with antisense oligonucleotide (ASO) inhibitors of miR-33 or miR-33* or a non-targeting control ASO. In macrophages treated with the control ASO, we observed numerous lipid bodies labeled with fluorescent dye BODIPY that colocalized with intracellular bacteria in the cytoplasm (Fig. 2c) . Following inhibition of miR-33 or miR-33*, the size and number of lipid bodies in Mtb-infected macrophages were reduced (Fig. 2c) . To determine whether miR-33 and miR-33* regulated the utilization of host-cell triglycerides by Mtb, we labeled macrophages with a BODIPY-C 16 fatty-acid analog before infection. Wild-type macrophages showed incorporation of lipid-droplet-derived BODIPYlabeled fatty acid into the intracellular bacteria, and this was greatly reduced in Mir33 −/− macrophages (Fig. 2d) . Together these data suggest that Mtb-induced expression of miR-33 and miR-33* in macrophages impaired mitochondrial fatty-acid oxidation to augment the cellular lipid stores that are imported into the bacilli to serve as a nutrient source during chronic infection.
Regulation of genes in the autophagy pathway by miR-33 Autophagy participates in lipid metabolism by promoting the catabolism of lipid droplets in lysosomes 27, 29 . To determine whether miR-33 and miR-33* regulated lipid-droplet turnover via autophagy, we treated BMDMs with oleic acid to form lipid droplets and assessed the ability of inhibitors of miR-33 and miR-33* to promote the clearance of these lipid droplets in the presence or absence of an inhibitor of lysosomal acid lipase (LAL), the lysosomal enzyme required for autophagy-mediated lipolysis. BMDMs treated with an ASO inhibitor of miR-33 or miR-33* had less lipiddroplet content than did BMDMs treated with the control ASO, (Fig. 2e) ; however this decrease was prevented following inhibition of LAL (Fig. 2e) . Using algorithms for the prediction of microRNA targets, we identified genes encoding products in the autophagy pathway as potential targets of human and mouse miR-33 and miR-33*, including genes encoding products involved in autophagosome formation (such as ATG5, ATG7, ATG12 and MAP1LC3B), lysosomal function (such as LAMP1 (which encodes the lysosomeassociated membrane protein LAMP-1) and LIPA (which encodes LAL)), and the regulation of autophagy (such as UVRAG, PRKAA1 and PRKAA2) (Supplementary Fig. 2 ). To investigate whether miR-33 and miR-33* regulate autophagy, we selected a subset of putative target genes encoding products involved in different stages of autophagy for further validation. We transfected HEK293 human embryonic kidney cells with 3′ UTR-luciferase reporter genes for human ATG5, ATG7, ATG12, LAMP1, UVRAG and MAP1LC3B (which encodes LC3B) in the presence of the homo sapiens (hsa) miRNA mimic hsa-miR-33a or a control mimic. The 3′ UTRluciferase activity of ATG5, ATG12, LAMP1, UVRAG and MAP1LC3B, but not that of ATG7, was lower in cells treated with hsa-miR-33a than in those treated with the control mimic (Fig. 3a) . Furthermore, THP-1 macrophages treated with hsa-miR-33a had lower expression of ATG5, ATG12, LAMP1 and MAP1LC3B protein than did control-mimic-treated macrophages ( Fig. 3a and Supplementary Fig. 3 ), which confirmed that the genes encoding these autophagy effectors were targets of miR-33. Similarly, the miRNA mimic hsa-miR-33a* reduced the 3′ UTR-luciferase activity of ATG5, ATG12, LAMP1, UVRAG and MAP1LC3B and the protein amounts of these gene targets ( Fig. 3b and Supplementary Fig. 3 ), A r t i c l e s which indicated a common role for hsa-miR-33a and hsa-miR-33a* in the regulation of the autophagy pathway.
Of the autophagy-related targets of miR-33 and miR-33* found in human cells, the mouse genes Atg5 and Lamp1 contain conserved miR-33-and miR-33*-binding sites. We found that the mouse (mmu) miRNA mimics mmu-miR-33 and mmu-miR-33* reduced the activity of the Atg5 and Lamp1 3′ UTR-luciferase reporters in HEK293 cells relative to their activity in control-mimic-treated HEK293 cells (Fig. 3c,d) . Furthermore, mouse peritoneal macrophages transfected with mmu-miR-33 and mmu-miR-33* had lower expression of ATG5 and LAMP1 protein than did control-mimic-treated macrophages (Fig. 3c,d and Supplementary Fig. 3 ), which confirmed that mouse Atg5 and Lamp1 were targets of miR-33 and miR-33*. Despite the predicted miR-33-and miR-33*-binding sites in the genes encoding cathepsin B (Ctsb) and LAL (Lipa), we observed no effect of mmu-miR-33 or mmu-miR-33* on the 3′ UTR activity of Ctsb or Lipa (Fig. 3c,d) . mRNA profiling of peritoneal macrophages transfected with mimics or inhibitors of miR-33 and miR-33* showed reciprocal regulation of Atg5, Lamp1 and Prkaa1 mRNA (that is, diminished after treatment with the mimics and enhanced after treatment with the inhibitors) (Fig. 3e,f) . Furthermore, Mir33 −/− macrophages (which lack both miR-33 and miR-33*) displayed higher expression of Abca1, Atg5, Lamp1 and Prkaa1 mRNA than that of wild-type macrophages (Fig. 3g) . Finally, consistent with the observed induction of miR-33 and miR-33* by Mtb, expression of miR-33 and miR-33* target genes that encode products in lipid-metabolic and autophagy pathways was lower in vivo in Mtbinfected (GFP + ) macrophages than in uninfected (GFP − ) macrophages from the same mice (Fig. 3h) . Together these data indicated that in Mtb-infected macrophages, elevated expression of miR-33 and miR-33* repressed genes encoding key products in the autophagy pathway. 
Regulation of FOXO3 and TFEB activation PCR array profiling revealed that overexpression and inhibition of miR-33 and miR-33* reciprocally regulated several genes encoding products in the autophagy pathway that did not contain miR-33-or miR-33*-binding sites ( Supplementary Fig. 4 ). The gene encoding AMPK is a target of miR-33 (ref. 22) , and AMPK has dual functions in promoting autophagy: it represses mTORC1 and promotes the activity of TFEB 30 and FOXO3 (ref. 14) . Thus, we focused on the AMPK-dependent activation of TFEB and FOXO3, transcriptional regulators of autophagy and lysosome-biogenesis gene programs. In HEK293 cells transfected with the human PRKAA1 or mouse Prkaa1 mRNA 3′ UTR reporter plasmid, the miR-33 mimic repressed 3′ UTR activity relative to its activity after treatment with the control mimic (Fig. 3a,c) . Furthermore, transfection of human THP-1 macrophages or mouse peritoneal macrophages with the miR-33 mimic reduced the expression of AMPKα protein (encoded by PRKAA1 and Prkaa1) relative to that of cells treated with the respective control mimic (Fig. 3a,c) . Macrophages treated with the ASO inhibitor of miR-33 had higher expression of Prkaa1 mRNA and AMPKα protein and more phosphorylation of AMPKα than did macrophages treated with the control ASO (Figs. 3e and 4a) . miR-33* is also predicted to target the gene encoding AMPKα, and overexpression and inhibition of miR-33* regulated the 3′ UTR activity of human PRKAA1 mRNA and mouse Prkaa1 mRNA and the expression and phosphorylation of AMPKα protein (Figs. 3 and 4a) . Although mouse Foxo3 and Tfeb lack binding sites for miR-33 or miR-33*, transfection of peritoneal macrophages with miR-33 or miR-33* reduced expression of Foxo3 and Tfeb and their downstream target genes (FOXO3: Atg4b, Atg12 and Map1lc3b; TFEB: Ctsb, Lipa and Uvrag), whereas treatment with the ASO inhibitor of miR-33 or miR-33* increased the expression of mRNA from these genes (Fig. 4b,c) . Furthermore, macrophages treated with the ASO inhibitor of miR-33 or miR-33* showed increased expression of FOXO3 and TFEB protein and localization of these transcription factors to the nucleus compared with that of macrophages treated with the control ASO ( Supplementary  Fig. 5 ), and these effects were abrogated in the presence of an AMPK inhibitor (Supplementary Fig. 5) . Likewise, the effects of overexpression or silencing of miR-33 and miR-33* on Foxo3 mRNAand Tfeb mRNA were abrogated in AMPK-deficient macrophages (Fig. 4d,e) . Similar to our findings obtained with inhibitors of miR-33 and miR-33*, Mir33 −/− macrophages displayed elevated expression and activation of FOXO3 and TFEB (Fig. 4f) , as well as increased expression of their downstream target genes (Fig. 4g) , compared with that of wild-type macrophages. Finally, expression of Foxo3 mRNA and Tfeb mRNA, as well as that of the genes regulated by the transcription factors they encode, was lower in vivo in Mtb-infected (GFP + ) macrophages than in uninfected (GFP − ) macrophages from the same mice (Fig. 4h) , consistent with elevated expression of miR-33 and miR-33* in Mtb-infected macrophages (Fig. 1e) . These observations indicated that miR-33 and miR-33* regulated autophagy through both direct targeting of autophagy effectors and repression of AMPK-dependent activation of the transcription of genes encoding products involved 
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A r t i c l e s in autophagy and lysosomes, and that these regulatory mechanisms were engaged during Mtb infection.
Regulation of cellular autophagy by the miR-33 locus
To assess the functional effects of the targeting of autophagy by miR-33 and miR-33*, we inhibited miR-33 or miR-33* in MEFs stably expressing LC3 tagged with both mCherry and EGFP, which can be used to track LC3 expression in autophagosomes and autophagolysosomes: the fluorescent tags EGFP and mCherry together emit a yellow signal in pH-neutral autophagosomes; however, following the fusion of autophagosomes with acidic lysosomes, the pH-sensitive EGFP signal diminishes, which results in stronger red fluorescence 31, 32 . In MEFs treated with the control ASO, LC3-EGFP and LC3-mCherry were diffusely expressed in the cytoplasm, whereas they were localized to punctate structures in MEFs treated with the ASO inhibitor of miR-33 or miR-33* (Fig. 5a) , consistent with enhanced autophagy initiation. MEFs treated with the ASO inhibitor of miR-33 or miR-33* showed a greater number of yellow autophagosomes and red autophagosomes-lysosomes, which resulted in an increased mCherry/ GFP ratio, relative to that of MEFs treated with the control ASO (Fig. 5a) , indicative of enhanced autophagy flux. Because cotransfection of HEK293 cells with miR-33 and miR-33* repressed the 3′ UTR of autophagy target genes more than did transfection of either miR-33 or miR-33* alone (Fig. 5b) , we investigated whether the two strands of pre-miR-33 had additive effects on autophagy. Treating peritoneal macrophages with inhibitors of both miR33 and miR-33* resulted in an additive increase in LC3 puncta relative to results obtained by inhibition of either miRNA alone (Fig. 5c) , which indicated that miR-33 and miR-33* cooperatively regulated autophagy. Mir33 −/− macrophages had more LC3 puncta than did wild-type macrophages (Fig. 5d) . Furthermore, the number of LC3 puncta in both wild-type macrophages and Mir33 −/− macrophages was increased by blockade of lysosomal degradation with chloroquine ( Fig. 5d) , indicative of functional autophagy flux.
To investigate whether Mtb limited autophagy-dependent antimicrobial responses by inducing miR-33 and miR-33*, we measured the colocalization of Mtb H37Rv with the adaptor p62, which tags bacteria for sequestration in LC3 + autophagosomes. Peritoneal macrophages treated with the ASO inhibitor of miR-33 or miR-33* contained more p62 + Mtb than did macrophages treated with the control ASO, and the p62-Mtb colocalization was further augmented by the treatment of peritoneal macrophages with anti-miR-33 and anti-miR-33* together (Fig. 6a) . Likewise, peritoneal macrophages treated with the ASO inhibitor of miR-33 or miR-33* contained more LC3 + bacteria than did macrophages treated with the control ASO, an effect that was further enhanced by treatment with ASO inhibitors of both miR-33 and miR-33* (Fig. 6b) . Finally, Mir33 −/− macrophages exhibited more association of p62 and LC3 with Mtb than that in wild-type macrophages when cells were infected with the virulent H37Rv strain but not when they were infected with the mutant ∆esxA strain, which fails to permeabilize the phagosome and trigger xenophagy 6 (Fig. 6c,d ). Together these data suggested that Mtb limited xenophagy by inducing expression of miR-33 and miR-33* in macrophages.
Promotion of Mtb clearance via inhibition of miR-33 and miR-33*
To investigate whether miR-33-and miR-33*-dependent repression of autophagy and lipid catabolism enhances Mtb survival, we assessed the viability and growth of Mtb in vitro and in vivo. We infected BMDMs with an Mtb strain expressing mCherry constitutively and GFP under the control of an anhydrotetracycline-inducible promoter 33 . After treatment with anhydrotetracycline, metabolically active bacteria express both GFP and mCherry, whereas dead or metabolically inactive bacteria express only mCherry. Treatment with the ASO inhibitor of miR-33 or miR-33* reduced the proportion of metabolically active Mtb compared with treatment with the control ASO when BMDMs were infected with wild-type Mtb but not when BMDMs were infected with the ∆esxA Mtb mutant ( Fig. 7a) . The magnitude of this decrease was similar to that seen in BMDMs treated with IFN-γ before infection (Fig. 7a) , a treatment that activates autophagy 3 . Furthermore, Mir33 −/− BMDMs contained fewer metabolically active Mtb than did wild-type BMDMs (Fig. 7b) , and similar results were obtained when Mtb viability was quantified by bacterial colony formation (Fig. 7c) . Notably, the ASO inhibitors of miR-33 and miR-33* failed to reduce bacterial viability in Atg16l1 −/− BMDMs, which lack an essential component of the autophagy elongation complex (Fig. 7d) ; this confirmed that the antimicrobial effects of silencing miR-33 and miR-33* were mediated by autophagy. Because the autophagy pathway is critical to both lipid catabolism (lipophagy) and bacterial degradation (xenophagy), the Atg16l1 −/− BMDMs should have been impaired in both. To determine the role of miR-33 and miR-33* specifically in xenophagy, we assessed Mtb survival in mouse BMDMs that lack the cytosolic sensor cGAS required for the initiation of xenophagy of Mtb 9-11 (Mb21d1 −/− ; called 'Cgas −/− ' here). As has been reported [9] [10] [11] , Mtb grew better in Cgas −/− BMDMs than in wild-type BMDMs ( Fig. 7e and Supplementary Fig. 6 ). Treatment with the ASO inhibitor of miR-33 or miR-33* restricted Mtb viability by 32% in wild-type BMDMs but only by 18% in the xenophagy-deficient Cgas −/− BMDMs, relative to its viability in their counterparts treated with control ASO (Fig. 7e) . Collectively, these results demonstrated that miR-33 and miR-33* regulated the intracellular survival of Mtb, in part through xenophagy.
To assess the effects of Mtb induction of the expression of miR-33 and miR-33* in vivo, we generated a model of macrophage deficiency in miR-33 using bone marrow transplantation, which has been shown to mediate donor engraftment of alveolar ma crophages by more than 90% (ref. and Tcfeb, than their expression in the lungs of WT→WT mice (Fig. 8a) . Furthermore, Mir33 −/− →WT mice had a lower bacterial burden in the lungs than that of WT→WT mice at 15, 30 and 53 d after infection (Fig. 8b) , which indicated that mice with hematopoietic miR-33 deficiency had an improved ability to clear Mtb in vivo. Collectively, these data supported the proposal of a role for miR-33 in limiting macrophage autophagy, lipid catabolism and, consequently, Mtb elimination (Supplementary Fig. 7 ). 
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A r t i c l e s but also from those of its passenger strand (miR-33*). Not all miRNAs conform to the conventional model in which the guide strand is 'preferentially' loaded onto the RISC, and published studies have identified various active miRNA* strands, including miR-126-3p and miR-126-5p 26, [35] [36] [37] . Unlike miR-33 and miR-33*, the two strands of the miR-126 duplex regulate distinct sets of target genes to protect hosts from endothelial damage and atherosclerosis 37 . Our findings that miR-33 and miR-33* repressed an overlapping set of target genes encoding products in the autophagy pathway suggested a 'double-hit' model in which both strands of the miR-33 locus act cooperatively to regulate a common biological pathway. We found that γ-Mtb and the cell wall constituents lipoarabinomannan and trehalose dimycolate were sufficient to induce the miR-33 locus, a response that depended on NF-κB and led to impaired fatty-acid β-oxidation and enhanced lipid-droplet accumulation. This was consistent with published studies showing that the formation of lipid bodies in response to mycobacteria does not require live bacilli, can be driven by lipoarabinomannan and is partially dependent on Toll-like receptor 2 (refs. 21,38) , as well as the observation that miR-33 expression is regulated by NF-κB 39 . Lipids are important in the physiology, metabolism and virulence of Mtb, but their role is incompletely understood. Lipid bodies serve as a secure sanctuary that shelters the bacteria from innate immunological defenses and provide a nutrient-rich environment for replication [40] [41] [42] [43] . Our results showed that by inducing the miR-33 locus, Mtb promoted macrophage lipid stores through two mechanisms: reduction of autophagy-mediated delivery of lipid droplets to lysosomes for LAL-mediated lipolysis, and inhibition of cellular fattyacid oxidation. The miR-33-driven lipid-body accumulation might work in concert with other anti-lipolytic mechanisms engaged by Mtb, such as activation of the G-protein-coupled receptor GPR109A that blocks the action of hormone sensitive lipase 20 . In miR-33-and miR-33*-deficient macrophages, the importation of cellular fatty acids by Mtb was much lower, which highlighted the importance of these host miRNAs in Mtb metabolism. Access to host lipids might be particularly important during latent infection, as lipid-laden bacteria acquire characteristics of dormant bacilli, including resistance to antimycobacterial drugs 19, 44 . These findings provide insight into the molecular pathways that lead to the foamy phenotype of Mtb-infected macrophages.
Trafficking through the autophagy pathway depends on the Mtb protein EsxA 6 , and a prevailing idea is that EsxA damages the phagosomal membrane 45, 46 , which leads to the activation of cytosolic sensors that promote xenophagy 6, [9] [10] [11] 47, 48 . Notably, the microbicidal effects of ASO inhibitors of miR-33 and miR-33* were markedly reduced in macrophages infected with the attenuated ∆esxA Mtb mutant relative to their effects in cells infected with the virulent H37Rv strain of Mtb, which demonstrated that the induction of autophagy by inhibition of miR-33 did not override the requirement for EsxA. The importance of autophagy in the microbicidal effects of inhibitors of miR-33 and miR-33* was indicated by the diminished activity of these ASOs in the absence of Atg16L1 and cGAS. The retention of antimicrobial activity by inhibitors of miR-33 and miR-33* in Cgas −/− macrophages, which are deficient in xenophagy but not lipophagy, probably reflected their additional effects on lipid metabolism.
Our data indicated that Mtb employed a previously unknown mechanism of evading autophagy by inducing the miR-33 locus to post-transcriptionally limit the autophagy machinery. Although our study did not discriminate the individual roles of AMPK and other autophagy effectors encoded by genes targeted by miR-33 and miR-33*, it has highlighted the importance of miRNAs as orchestrators of pathway control that can have marked effects on biological processes by causing modest decreases in the expression of multiple genes encoding products involved in a given pathway. It is likely that the influence of miR-33 in innate immune responses extends beyond Mtb, given that autophagy has well-described roles in host defense and inflammatory disorders and that lipid bodies are increasingly appreciated as being important for innate immunity.
METhODS
Methods and any associated references are available in the online version of the paper.
